Synchron publishes SWITCH trial peer-reviewed results — 100% device survival at 2 years
Summary
Synchron published the full peer-reviewed SWITCH trial results in Nature Medicine, reporting 100% device survival at 2 years in all 10 patients, no serious adverse events, and communication rates of 14-40 characters per minute using the Stentrode BCI for cursor control and text entry. Importantly, 3 of 10 patients showed device-free residual motor function improvements.
Why it matters
Peer-reviewed 2-year safety data with 100% device survival for an endovascular BCI is a landmark publication. The unexpected finding of device-free motor improvement in 30% of patients suggests the Stentrode may promote neuroplasticity beyond its communication function — a potentially transformative secondary finding.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial